Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 25
Open 67.18
Bid (Size) 66.94 (9)
Ask (Size) 67.00 (11)
Prev. Close 67.18
Today's Range 67.18 - 67.18
52wk Range 60.47 - 87.67
Shares Outstanding N/A
Dividend Yield 1.49%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
From AstraZeneca
Via Business Wire
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer
Via The Motley Fool

Performance

YTD
-1.78%
-1.78%
1 Month
+3.69%
+3.69%
3 Month
-17.23%
-17.23%
6 Month
-15.21%
-15.21%
1 Year
+5.80%
+5.80%

More News

Read More
Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
From AstraZeneca
Via Business Wire
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
Via Benzinga
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
Via Benzinga
Exposures Product Safety
IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer
Via Benzinga
Exposures Product Safety
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
From AstraZeneca
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'
Via Benzinga
3 Momentum Stocks Soaring Into 2025 and Beyond
Via MarketBeat
Topics Stocks
Exposures US Equities
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
Via MarketBeat
Topics Government
Exposures COVID-19 Political Product Safety
TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns
Via Benzinga
Exposures Product Safety
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
Via The Motley Fool
This AstraZeneca Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
From AstraZeneca
Via Business Wire
Not-So-Big Pharma
Via Talk Markets
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Via Benzinga
Exposures Product Safety
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It
Via Benzinga
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill
Via Benzinga
Topics Government
Exposures Political
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower
Via Benzinga
Topics Government
Exposures Political
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.